|
07 Jun 2019 |
Eloxx Pharmaceuticals Presents Positive New Data for Lead Investigational Drug, ELX-02, at the 42nd European Cystic Fibrosis Society Conference (ECFS)
|
|
07 Jun 2019 |
NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough
|
|
07 Jun 2019 |
Boston Biomedical, Inc. Announces the Continuation of the Phase 3 CanStem303C Study of Napabucasin in Patients with Advanced Colorectal Cancer Following Interim Analysis
|
|
07 Jun 2019 |
Astex and Otsuka Announce Results of the Phase 3 ASCERTAIN Study of the Novel Oral Cedazuridine/Decitabine Fixed-Dose Combination (ASTX727) in Patients with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)
|
|
07 Jun 2019 |
US FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis
|
|
07 Jun 2019 |
Goldfinch Bio Initiates Phase 1 Clinical Trial of GFB-887 for Kidney Disease
|
|
07 Jun 2019 |
vTv Therapeutics Announces Positive Topline Results from Part 1 of the Phase 2 Simplici-T1 Trial in Patients with Type 1 Diabetes
|
|
07 Jun 2019 |
Vivacelle Bio Announces Submission of an IND Application with U.S. FDA for VBI-S, an Injectable Fluid for the Treatment of Patients with Severe Septic Shock
|
|
06 Jun 2019 |
Calquence Phase III ELEVATE-TN trial met primary endpoint at interim analysis in previously-untreated chronic lymphocytic leukaemia
|
|
06 Jun 2019 |
Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis
|
|
06 Jun 2019 |
Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis
|
|
04 Jun 2019 |
New data on Vitrakvi® (larotrectinib) in TRK fusion cancer patients with brain metastases or primary central nervous system (CNS) tumors
|
|
04 Jun 2019 |
Long-term Survival Benefit Shown for Metastatic Melanoma Patients Treated with Novartis Tafinlar® + Mekinist®
|
|
04 Jun 2019 |
LYNPARZA® (olaparib) Phase 3 SOLO3 Trial Demonstrated a 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patients Receiving Chemotherapy
|
|
04 Jun 2019 |
FDA Approves Merck’s ZERBAXA® (ceftolozane and tazobactam) 3g Dose for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
|
|
04 Jun 2019 |
Janssen Seeks to Expand Use of ERLEADA® (apalutamide) in the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer
|
|
04 Jun 2019 |
Phase III Study Showed XOFLUZA (Baloxavir Marboxil) is Effective at Preventing Influenza Infection
|
|
04 Jun 2019 |
Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Pemigatinib as a First-Line Therapy for Cholangiocarcinoma
|
|
04 Jun 2019 |
ARS Pharmaceuticals Announces Results from EPI-04 Clinical Study of ARS-1 Intranasal Epinephrine Spray in Allergy Patients with Allergic Rhinitis
|
|
04 Jun 2019 |
Allegro Ophthalmics Announces Positive Topline Vision Results of Phase 2 Study Evaluating Risuteganib in Patients with Intermediate Dry Age-Related Macular Degeneration
|
|
03 Jun 2019 |
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
|
|
03 Jun 2019 |
Adastra Pharmaceuticals Announces Positive Interim Data from Phase 1b Clinical Trial of Zotiraciclib in the Treatment of Recurrent Malignant Gliomas
|
|
03 Jun 2019 |
AMG 510 is the First KRASG12C Inhibitor to Reach Clinical Stage After Three Decades of RAS Research
|
|
03 Jun 2019 |
Ironwood Pharmaceuticals and Allergan Initiate Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D
|
|
03 Jun 2019 |
Qurient Announces Positive Phase 2a Data of Novel Antibiotic for the Treatment of Tuberculosis
|
